Perspective Therapeutics Inc
CATX
Get informed when a big investor buys or sells
+ FollowMarket Cap$354.68M
Close$
$0.37
88.1% downside
Current Fair Value
88.1% downsideOvervalued by 88.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $354.68 Million |
|---|---|
| Enterprise Value | $335.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.4 |
| Beta | 1.8 |
| Outstanding Shares | 73,813,000 |
Return
| Return on Equity | -35.95% |
|---|---|
| Return on Assets | -29.70% |
| Return on Invested Capital | -22.32% |
Valuation & Multiples
| P/E Ratio | -1.99 |
|---|---|
| PEG | 5.98 |
| Price to Sales | - |
| Price to Book Ratio | 0.78 |
| Enterprise Value to Revenue | 915.74 |
| Enterprise Value to EBIT | -4.22 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$90,528
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$74,681
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Perspective Therapeutics Inc
64 employees
CEO: Lori Woods Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.